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Background: Comorbidity in patients with diabetes is associated with poorer health and increased cost. The aim of
this study was to investigate the prevalence and ingredient cost of comorbidity in patients ≥ 65 years with and
without medication treated type 2 diabetes using a national pharmacy claims database.
Methods: The Irish Health Service Executive Primary Care Reimbursement Service pharmacy claims database, which
includes all prescribing to individuals covered by the General Medical Services scheme, was used to identify the
study population (≥ 65 years). Patients with medication treated type 2 diabetes (T2DM) were identified using the
prescription of oral anti-hyperglycaemic agents alone or in combination with insulin as a proxy for disease
diagnosis. The prevalence and ingredient prescribing cost of treated chronic comorbidity in the study population
with and without medication treated T2DM were ascertained using a modified version of the RxRiskV index, a
prescription based comorbidity index. The association between T2DM and comorbid conditions was assessed using
logistic regression adjusting for age and sex. Bootstrapping was used to ascertain the mean annual ingredient cost
of treated comorbidity. Statistical significance at p < 0.05 was assumed.
Results: In 2010, 43165 of 445180 GMS eligible individuals (9.7%) were identified as having received medication for
T2DM. The median number of comorbid conditions was significantly higher in those with T2DM compared to
without (median 5 vs. 3 respectively; p < 0.001). Individuals with T2DM were more likely to have ≥ 5 comorbidities
when compared to those without (OR = 2.82, 95% CI = 2.76-2.88, p < 0.0001). The mean annual ingredient cost for
comorbidity was higher in the study population with T2DM (€1238.67, 95% CI = €1238.20 - €1239.14) compared to
those without the condition (€799.28, 95% CI = €799.14 - € 799.41).
Conclusions: Individuals with T2DM were more likely to have a higher number of treated comorbid conditions
than those without and this was associated with higher ingredient costs. This has important policy and economic
consequences for the planning and provision of future health services in Ireland, given the expected increase in
T2DM and other chronic conditions.
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Diabetes is increasingly being recognised as a major glo-
bal health concern [1]. The prevalence of diabetes has
increased globally [2] and it is projected that worldwide
the prevalence will increase from an estimated 2.8% in
the year 2000 to 4.8% by 2030 [3]. This increase has
been attributed to a rise in the incidence of type 2 dia-
betes (T2DM) [1], the most common type of diabetes
[4], and has been driven primarily by increasing levels of
obesity, inactivity and population aging [1].
Comorbidity, the co-existence of one or more
additional conditions in persons with a specified index
medical condition [5], is highly prevalent in patients
with diabetes [6]. In the United States the majority of
adults with diabetes have more than one comorbid con-
dition [6] and 40% have 3 or more conditions [7]. A
number of different frameworks have been developed
that categorise comorbid conditions according to their
influence on the clinical management of the index con-
dition [8]. The most recent was developed by Piette &
Kerr [9] and has since been used in a number of pub-
lished studies [10-12]. The original paper classified
chronic comorbid conditions as being either concordant
or discordant with diabetes. Concordant conditions are
those associated with diabetes, i.e. they represent part of
the same overall pathophysiological risk profile and
share the same medical management plan (e.g. hyperten-
sion, ischemic heart disease, and hyperlipidemia) [9,10].
In contrast, discordant conditions are not pathophysio-
logically associated with diabetes and consequently their
management may be different (e.g. arthritis, chronic ob-
structive pulmonary disease, depression) [9,10].
In terms of the patient, comorbidity is associated with
reduced health status, decreased quality of life and
increased risk of mortality [5]. Patients with diabetes are
required to manage their condition in order to obtain
and maintain optimal outcome measures [13]. Depend-
ing on the symptoms and severity of the comorbid
condition(s) present, patients’ prioritisation and self-
management may be compromised and/or compli-
cated [14,15]. Patients with multiple conditions may
encounter conflicting medical advice and fragmented
care pathways which may provide a barrier to effect-
ive self-management [15,16]. The management of
comorbid conditions may also indirectly affect dia-
betes self care by representing an additional demand
on patient time, effort and financial resources [9].
In terms of the health service, comorbidity is asso-
ciated with increased health care utilisation [17] and
economic cost [18-21]. In the Irish CODEIRE study,
which estimated the economic cost of diabetes in Ire-
land, complications related to diabetes accounted for the
majority (61.7%) of all patient costs [22]. This is consist-
ent with the results of previous research conducted inEurope [23]. However, these studies did not include any
cost analysis relating to discordant comorbidity.
It is evident from the published literature, that comor-
bidity has substantial implications in terms of self care
and health service provision. At present, few Irish stud-
ies have examined the subject of comorbidity in relation
to diabetes. Those that have been published have con-
centrated on the prevalence or impact of a single comor-
bid condition [24-26]. The aim of this study was to
investigate and estimate the prevalence, type and ingre-
dient cost of chronic comorbid conditions occurring in
elderly Irish individuals with T2DM, compared to those
without T2DM, using a modified version of the RxRisk
V comorbidity index, based on data obtained from a
national pharmacy claims database.
Methods
A retrospective cross-sectional study, utilising the Irish
Health Service Executive Primary Care Reimbursement
Service (HSE–PCRS) national pharmacy claims database
was conducted using data from 2010. The HSE-PCRS
database is used primarily to provide financial reim-
bursement to health care professionals involved in pri-
mary care, for the provision of health services and
prescription medications under a number of different
state provided health care schemes, including the
General Medical Services scheme (GMS) [27]. The GMS
scheme provides eligible individuals, termed “medical
card” patients, with access to free health care, routine
dental services and prescription medication [27]. Eligibil-
ity for the GMS scheme is based on an individual being
ordinarily resident in Ireland and the outcome of a gross
income means assessment. The weekly income threshold
for GMS scheme eligibility is dependent on the marital
status and age of the claimant [27]. Older individuals
aged ≥ 70 years were automatically entitled to a medical
card regardless of their income from July 2001 – Dec
2008 [27]. In 2010 the GMS scheme covered half
(50.4%) of the Irish population aged between 65–69 years
and 98.4% of the population aged ≥ 70 years or more
(based on population estimates) [28,29].
The HSE-PCRS collates information on dispensed pre-
scribed medication for the GMS scheme on a monthly
basis. Medications dispensed through the GMS scheme
are recorded in the HSE-PCRS and are coded using the
WHO Anatomical Therapeutic Chemical (ATC) classifi-
cation system. In addition to providing details on medi-
cations dispensed to eligible individuals, the HSE-PCRS
pharmacy claims database also contains demographic
information about the claimant such as age, sex and
region of residence. The HSE-PCRS pharmacy claims
database does not contain clinical information regarding
diagnosis, clinical outcome or over the counter (OTC)
medication which may be obtained without a prescription
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The study population consisted of elderly individuals
aged ≥ 65 years who were eligible for inclusion in the
GMS scheme and who had received medication docu-
mented in the HSE-PCRS database during the study
period. The study population was categorised by sex and
subdivided into three age groups; 65–69, 70–74 and ≥
75 years. Individuals with T2DM were identified using
the prescription of any oral anti-hyperglycaemic (OAH)
agent (ATC, A10B) either prescribed alone or in com-
bination with any type of insulin (ATC, A10A), as a
proxy for disease diagnosis. For the purposes of this
paper the study population identified as having received
medication for T2DM is referred to as the T2DM group.
Individuals who did not receive any OAH agents
during the study period were used as the comparator
group for the analysis, and are referred to as the
non T2DM group.
The burden of pharmacologically treated comorbidity
in both the T2DM and the non T2DM group was ascer-
tained using a modified version of RxRiskV index. The
RxRiskV is a previously validated pharmaceutical based
comorbidity index which is calculated from the sum of
45 potential disease groups derived from prescribing
data using ATC classification codes [31]. The RxRiskV
index was adapted for the purposes of the current study
to include updated ATC codes for medications currently
licensed in Ireland. Appendix 1 lists the medications and
ATC codes used in the current study. In its original
form, individuals were classified as having one of the
conditions listed in the RxRiskV index if they had
received at least one prescription filled for a disease class
during a given study period [31]. This was modified in
the present study to reflect the chronic nature of disease
categories listed in the RxRiskV index. In the present
study individuals were assumed to have one of the dis-
eases if they received at least three consecutive prescrip-
tions of a medication representing a specific disease
class. In order to include the maximum number of eld-
erly individuals fitting these criteria the study period was
extended to sixteen months to include the last two
months of 2009 and the first two months of 2011. Dia-
betes was excluded from the modified version of the
RxRisk V index as it was the disease of interest. This
modified version of the RxRisk V index is referred to as
RxRiskV (mod). Ethical approval for this study was not
required as the analysis for this study was carried out on
an anonymised database.
Data analysis
The comorbidity score was determined by calculating
the maximum RxRiskV (mod) score for each individualand then grouping them according to their T2DM sta-
tus. As the proportion of the study population with
more than 10 conditions was small (0.78%) individuals
with ≥ 10 were grouped together into a single category.
The median comorbidity level, interquartile range and
the prevalence of the most common comorbid condi-
tions defined by the RxRiskV (mod) was calculated in
those with and without T2DM. The association between
T2DM and individual conditions in the RxRiskV (mod)
index was assessed using the Χ2 test. The median num-
ber of comorbid conditions in the T2DM group was
chosen as a proxy measurement to define low (<median)
versus high (> =median) comorbidity. The association
between T2DM and low versus high comorbidity was
subsequently examined using the X2 test. Logistic regres-
sion analysis was performed to examine the relationship
between the comorbid conditions and T2DM and
adjusted for age (ref: 65–69 years) and sex (ref: female).
The resulting associations are displayed as adjusted odds
ratios with 95% confidence intervals (OR, 95%CI).
The total annual ingredient cost was calculated by
summing the medication cost for each category included
in the RxRiskV (mod) index for 2010. Bootstrapping was
used to allow the comparison of means given the skew-
ness of the cost data and replicated 2000 times so as to
attain the 95% confidence interval [32]. The cost data
were subsequently stratified by age, sex, T2DM status
and number of comorbid conditions. SAS version 9.1
was used for the data analysis. Statistical significance at
p <0.05 was assumed.
Results
During January to December 2010, 445180 individuals
aged ≥ 65 received at least three consecutive prescrip-
tions recorded in the HSE-PCRS pharmacy claims data-
base. Forty three per cent (191690 individuals) of the
sample population were male. Half (50.3%) of the indivi-
duals were ≥ 75 years, 26.9% were 70–74 years and
22.8% were aged 65–69 years. In the study population
43165 individuals received three or more consecutive
prescriptions for OAH agents. This represents a preva-
lence of 9.7% for T2DM in this elderly population. The
prevalence of T2DM in this population was significantly
higher in males (12.1%) compared to females (7.9%) (p <
0.0001). The prevalence of T2DM was highest in the mid-
dle age category 70–74 years, (10.1%) and lowest in the
oldest study population ≥75 years (9.4%) (p < 0.0001).
The median number of comorbid conditions was found
to be significantly higher in the group with T2DM (5 con-
ditions, IQR 3–6) compared to the non T2DM group (3
conditions, IQR 1–5). The association between low versus
high comorbidity was significant (X2 =16355, df =10, p <
0.0001). The odds of having ≥ 5 comorbid conditions was
almost three times higher in the T2DM group compared
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2.88, p < 0.0001). In the study population with T2DM,
females in the youngest (65–69 years) and middle (70–
74 years) age categories had a higher median number of
comorbid conditions when compared to males (5 vs. 4
conditions) (Table 1). In the non T2DM group there was
no significant difference in the median number of como-
rbid conditions when stratified by age group and sex
(Table 1).
The prevalence of 35 of the 45 conditions listed in
the RxRiskV (mod) index was significantly higher in
the group with T2DM than in the non T2DM group.
The results from the logistic regression analysis on
individual comorbid conditions included in the
RxRiskV (mod) index with a prevalence of ≥ 10% in
the study population showed an increased likelihood
of individuals with T2DM having received a prescrip-
tion for these conditions. The prevalence of co-
prescribing and the odds ratios adjusted for age and
sex are summarised in Table 2.
The majority of comorbidity in the group with T2DM
related to concordant conditions or therapies associated
with the cardiovascular system (CVS). A number of dis-
cordant conditions were also significantly co-prescribed
more often in the group with T2DM (p < 0.0001). The
most prevalent of these were gastric reflux and peptic
ulcer, depression and chronic airway disease. The preva-
lence of co-prescribed medication for osteoporosis was,
however, significantly lower in the group with T2DM
(OR = 0.73, 95%CI = 0.70-0.75, p < 0.0001) when com-
pared to the control group.
The mean annual ingredient cost of comorbidity in
the study population with T2DM was higher (€1238.67,
95% CI = €1238.20 - €1239.14) than for the control
group (€799.28, 95% CI = €799.14 - € 799.41). When the
cost data was stratified by age and sex, a similar signifi-
cant difference between groups was observed in both
men and women with the mean ingredient cost of
comorbidity increasing with increasing age (Table 3).
The mean drug ingredient cost of comorbidity wasTable 1 Median number of comorbid conditions stratified by
Sex Age T2DM group
(n 43165)
T2DM median no. of com
conditions [IQR]
Male
65 - 69 5535 4 [3 – 6]
70 - 74 6948 4 [3 – 6]
≥75 10690 5 [3 – 6]
Female
65 - 69 4610 5 [3 – 6]
70 - 74 5109 5 [4 – 6]
≥75 10273 5 [4 – 7]higher in women compared to men across all age cat-
egories in the study population with T2DM, and was
also higher in women in the middle (70–74 years) and
oldest (≥ 75 years) age categories in the study population
without T2DM (Table 3). Further analysis of the cost
data, stratified by number of comorbid conditions, found
that the mean annual ingredient cost of chronic comor-
bidity was higher in the non T2DM group compared to
the group with T2DM in patients with a low number
(≤ 2) of comorbid conditions. Conversely, in the study
population with a high number (≥ 4) of comorbid condi-
tions, the mean annual ingredient cost was higher in the
T2DM group compared to the group without T2DM.
There was no difference in the mean annual ingredient
cost between the two groups in patients with three
comorbid conditions. These results are summarised
in Table 3.
Discussion
This is the first large scale study using a national phar-
macy claims database in Ireland to investigate the preva-
lence, type and ingredient cost of comorbidity present in
the elderly GMS eligible population (≥ 65 years) with
and without T2DM. It has also successfully modified the
RxRiskV index to include the ATC codes of pharmaco-
logical agents currently licensed for use in Ireland and
strengthened the definition of “chronic” used in the ori-
ginal version, by specifying that an individual must have
received a minimum of three consecutive prescriptions
for a disease class. The results show that during the
study period the elderly population with T2DM had a
higher level of comorbidity and associated drug costs
when compared to the non T2DM group. These results
are similar to the findings of previous studies that inves-
tigated comorbidity in diabetic populations in Finland
and Australia [33,34].
Overall, cardiovascular-related concordant conditions
accounted for a substantial proportion of the comorbid-
ity in the study population both with and without
T2DM. A higher level of cardiovascular-relatedage, sex and T2DM status (Total n = 445,180)
orbid Non T2DM group
(n 402015)
Control median no. of comorbid
conditions [IQR]
38606 3 [1 – 4]
50023 3 [1 – 5]
79888 4 [2 – 5]
52770 3 [1 – 4]
57726 3 [1 – 5]
123002 4 [2 – 6]
Table 2 Chronic medical conditions included in the RxRiskV (mod) index with ≥10% prevalence in the study
population
RxRiskV (mod) category Non T2DM (%) T2DM (%) Adjusted Odds Ratio ** 95% CI
Concordant conditions/therapies
Cardiovascular system
Hyperlipidemia 42.6 78.5 4.95 4.83 - 5.06
Anti-platelet agents* 39.8 71.7 3.84 3.76 - 3.93
Heart disease 39.4 61.4 2.44 2.39 - 2.49
Hypertension 21.7 32.2 1.79 1.75 - 1.83
Discordant conditions/therapies
Digestive system
Gastric reflux and peptic ulcer 34.5 46.4 1.67 1.63 - 1.70
Mental health
Depression 16.0 20.5 1.46 1.43 - 1.50
Respiratory system
Chronic airway disease 14.4 18.6 1.35 1.32 - 1.40
Musculoskeletal
Osteoporosis 14.3 9.3 0.73 0.70 - 0.75
Pain management
Anti-inflammatory agents 13.0 14.1 1.14 1.11 - 1.18
Pain (Opiates) 10.0 12.9 1.42 1.38 - 1.47
* Non specific marker for cardiovascular disease.
** adjusted for age and sex.
Table 3 Mean annual ingredient cost of chronic comorbidity in the study population with and without T2DM
Sex Age (yrs) T2DM group Non T2DM group Cost ratio *
Male
65-69 1183. 43 [1182.12, 1184.75] 683. 85 [683.41, 684.28] 1.73
70-74 1184. 35 [1183.22, 1185.47] 744. 02 [743.67, 744.37] 1.59
≥75 1245. 51 [1244.65, 1246.36] 871. 33 [871.02, 871.65] 1.45
Female
65-69 1223. 89 [1222.43, 1225.31] 667.52 [667.16, 667.88] 1.83
70-74 1293. 06 [1291.74, 1294.38] 764.89 [764.57, 765.22] 1.69
≥75 1279. 10 [1278.05, 1280.14] 882.95 [882.71, 883.18] 1.45
No. of comorbid conditions
0 0 0 1
1 193. 45 [192.82, 194.08] 225.02 [224.86, 225.17] 0.86
2 386. 59 [385.99, 387.20] 414.52 [414.34, 414.69] 0.93
3 628. 65 [628.10, 629.21] 628.35 [628.15, 628.54] 1
4 897. 08 [896.42, 897.74] 874.86 [874.60, 875.11] 1.03
5 1186. 88 [1186.14, 1187.62] 1153.70 [1153.38, 1154.02] 1.03
6 1485. 14 [1484.16, 1486.13] 1454.08 [1153.38, 1154.02] 1.02
7 1807.74 [1806.40, 1809.08] 1764.68 [1764.05, 1765.31] 1.02
8 2130. 86 [2129.05, 2132.67] 2078.91 [2078.03, 2079.79] 1.03
9 2461. 44 [2458.71, 2464.17] 2436.44 [2435.00, 2437.87] 1.01
≥10 3151. 03 [3146.39, 3155.67] 3023.80 [3022.13, 3025.46] 1.04
[95% Confidence Interval].
* T2DM group : non T2DM group.
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before [33,35] and reflects the established association be-
tween T2DM and conditions affecting the cardiovascular
system [36]. The high rate of co-prescription of anti-
platelet therapy, anti-hypertensive medication and
cholesterol lowering agents in patients with T2DM
also suggests prescriber adherence to the current
Irish cardiovascular health policy which advocates
active and aggressive management of cardiovascular
risk factors in individuals with diabetes [37].
The most prevalent discordant comorbid conditions in
the current study were gastric reflux/peptic ulcer, de-
pression and chronic airway disease. This is consistent
with the findings of a previous Australian study that
used the RxRiskV index to examine the level of comor-
bidity in a cohort of veterans with T2DM [34]. It is pos-
sible however, that the higher frequency of co-
prescribing treatment for gastric reflux/peptic ulcer in
the group with T2DM may reflect the use of proton
pump inhibitors (PPIs) as a gastroprotective agent in
patients taking the OAH agents rather than the presence
of gastrointestinal morbidity.
Previous studies that have investigated comorbidity in
populations with diabetes have also reported an increase
in the prevalence of depression [38,39]. The frequency
of co-prescription of anti-depressant medication in the
current study was significantly higher in the group with
T2DM. There is conflicting evidence as to whether there
may be a physiological basis for the observed association
between diabetes and depression or whether it is due to
psychosocial stress associated with having a chronic con-
dition [40]. There is evidence, however, to suggest that
the presence of comorbid depression in individuals with
diabetes is associated with poorer medication adherence
[41] and an increased risk of diabetes related complica-
tions [42]. It is imperative therefore, that depression in
patients with T2DM is recognised and treated given the
adverse outcomes associated with such comorbidity.
Osteoporosis was the only condition included in the
RxRiskV (mod) index with a prevalence of ≥10% in the
study population as a whole that was prescribed for less
frequently in the group with T2DM. This finding is per-
haps unexpected as a recent meta-analysis demonstrated
that individuals with diabetes have an increased risk of
various types of bone fracture [43]. It is possible that the
result of the present study may infer an inadequacy in
the level of prescribing anti-osteoporotic medication to
elderly individuals with T2DM.
Research has shown that elderly patients with multiple
unrelated medical conditions may be undertreated [44].
Health professionals attending to patients with chronic
conditions must remain vigilant for other disorders to
ensure they are treated appropriately [44]. This is par-
ticularly important, considering information relating tothe care of patients with multiple conditions is scarce
[5]. Evidence based guidelines established for the treat-
ment of diabetes and other major chronic conditions
have focused too narrowly on the management of single
conditions [9] and may not be appropriate for patients
with comorbidity unrelated to the index condition. This
should be taken into consideration when proposing new
health strategies. Policy makers should alter the focus of
initiatives away from individual diseases towards policies
that reflect the holistic requirements of individuals with
multiple conditions [7,45].
The economic liability posed by diabetes has been dis-
cussed extensively in the published literature [22]. It has
been well documented that the treatment of complica-
tions associated with diabetes account for the majority
of the economic cost associated with patient care [22].
The cost analysis presented in the current study focuses
solely on the ingredient cost of prescription drugs and
did not include other expenses such as health care util-
isation or patient out-of-pocket expenses. The results of
the current analysis suggest that the treatment of comor-
bid conditions (both concordant and discordant) pose a
significant additional annual ingredient cost in the GMS
eligible elderly population with T2DM compared to the
study population without the condition. It would, there-
fore, be advisable that both types of comorbidity be
taken into consideration in future economic evaluations
of costs associated with diabetes.
The results of this study have important clinical
implications for both patients and health profes-
sionals. There are also substantial economic implica-
tions for decision makers responsible for providing
the most cost-effective health care. The results of
the current study indicate that those with T2DM
have greater number of comorbid conditions, both
related and unrelated to diabetes, and that these are
associated substantial increased cost. Increased edu-
cation and earlier intervention programmes for
patients with diabetes are needed so as to avoid the
costly consequences of poor adherence and manage-
ment of their condition. A structured management
care programme provided in general practice, in
conjunction with a multi-disciplinary team of health
professionals; with direct and immediate access to
specialist services as required, would facilitate this
greatly. In Ireland, this type of programme has been
implemented in the Midlands health region for
patients with diabetes and has produced encouraging
results [46]. The nationwide implementation of this
type of programme could yield an overall improve-
ment in patient management and costs associated
with diabetes.
The present study has a number of limitations.
The HSE-PCRS pharmacy claims database upon
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contain clinical diagnoses. As a result patients with
T2DM were identified in study population using the
prescription of any OAH agents, with or without in-
sulin, as a proxy for disease diagnosis. This defin-
ition was unable to take into account patients with
T2DM who were treated using diet alone. In spite of
this methodological limitation it is likely that the
present study has captured the majority of diagnosed
T2DM in the study population, given the results of a
previous community based study that reported that
the majority of patients (74%) with T2DM were trea-
ted with OAH agents [47]. In addition, the current
study was unable to take into account patients with
medication treated T2DM who did not meet the eli-
gibility criteria for the GMS scheme. It is possible
that non medical card patients may have received
their diabetes medication through other community
drug schemes such as the Long Term Illness (LTI)
scheme or Drugs Payment Scheme (DPS) or paid for
their medications privately. In 2010, medical card
holders represented a very high proportion of the
Irish elderly population ≥ 70 years (98.4%). It is,
therefore, likely that the results of the present study
represent an accurate account of medication treated
T2DM, comorbidity and the associated ingredient
cost in this age group. For the age group 65–
69 years, only half are eligible for the GMS scheme,
which may represent a slightly more deprived and
sicker population. Previous research has indicated
that medical card holders on average visit their doc-
tor more frequently per year [48] and have poorer
health [49] when compared to non medical card
holders. There are limitations to using the bootstrap-
ping methods including the assumption that the dis-
tribution of the data from the sample is a reasonable
estimate of the population distribution from which it
came. Given the very large sample size and the high
percentage of the population captured this is unlikely
to be a major source of bias. There may also have
been some sampling error in the selection of random
samples in the bootstrap procedure, but with 2000
samples chosen this is unlikely. Finally, a medication
listed for one disease category in the RxRiskV (mod)
may have a number of licensed indications for use.
In order to limit the effect of this in the present
study, medications with more than one indication
were assigned to a single disease category which
reflected the highest ranked licensed indication.
Conclusion
This study has shown that older patients with T2DM
in Ireland have a greater prevalence of comorbidity
when compared to those without the condition. Ithas also shown increased economic cost in terms of
drug expenditure for both concordant and discordant
comorbidity in this study population. These findings
highlight the need for health policy makers and
economists to ensure that both concordant and dis-
cordant comorbid conditions are taken into account
when planning for future health care needs of those
with diabetes.
Appendix I
List of ATC codes used in the RxRiskV (mod)
Alcohol dependency [N07BB03, N07BB04, N07BB01]
Allergies [R01AC, R01AD, R06AD02, R06AD03,
R06AD04, R06AD05, R06AD06, R06AD07, R06AD08,
R06AD09, R06AD52, R06AD55, R06AE, R06AK, R06AX,
Excluding R06AX27 R06AX28 R06AX53 R06AX58]
Anti-coagulation therapy [B01AA03 B01AA04,
B01AA07 - B01AA11, B01AB01, B01AB02, B01AB04
- B01AB06, B01AB10]
Anti-platelet therapy [B01AC04 - B01AC19, B01AC30,
B01AC22, B01AC23]
Anxiety [N05BA01 - N05BA12, N05BB01]
Arrhythmia [C01AA05, C01BA01-C01BD01]
Angina [C01DA02, C01DA04, C01DA05, C01DA07,
C01DA08, C01DA09,
C01DA13, C01DA14, C01DX16, C01EB15, C01EB17,
C01EB18]
Benign prostate hypertrophy [G04CA02-G04CA03]
Bipolar disorder [N05AN01]
Chronic Heart failure - Must have both loop diur-
etic [C03CA, C03CB, C03CC01, C03DA] and ace in-
hibit [C09AA01, C09AA02, C09AA03, C09AA04,
C09AA05, C09AA06, C09AA07, C09AA08, C09AA09,
C09AA10, C09CA06, C09CA07, C09CA01, C09CA03]
Dementia [N06DA02, N06DA03, N06DA04, N06DX]
Depression [N06A]
End stage renal disease [B03XA, V03AE02, V03AE03,
and A11CC]
Epilepsy [N03AA01-N03AA04, N03AA30, N03AB01-
N03AB05 N03AB52,
N03AB54, N03AC01, N03AC02, N03AC03, N03AD01,
N03AD02, N03AD03, N03AD51, N03AE01, N03AF01,
N03AF02, N03AG01, N03AG02, N03AG03, N03AG04,
N03AG05, N03AG06, N03AX]
Gastric-oesophageal reflux disorder & Peptic ulcer
[A02B]
Glaucoma [S01EA01, S01EA02, S01EA03, S01EA04,
S01EA05, S01EA51”
S01EB01, S01EB02, S01EB03, S01EC03, S01EC04,
S01ED01, S01ED02, S01ED03, S01ED04, S01ED05,
S01ED06, S01ED51, S01ED52, S01ED54, S01EE01,
S01EE02, S01EE03, S01EE04, S01EX01, S01EX02]
Gout [M04AA01, M04AA02, M04AA03, M04AA51,
M04AB01, M04AB02, M04AB03, M04AB04, M04AC01]
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HIV [J05AE01 - J05AE08, J05AF01 - J05AF11, J05AG01,
J05AG02, J05AG03 J05AR01-J05AR06, J05AX07]
Hyperkalaemia [V03AE01]
Hyperlipidemia [C10AA, C10AB, C10AC, C10AD,
C10AX, C10BA, C10BX]
Hypertension [C03AA, C03AB, C03AH, C03AX01,
C02CA04”
C03BA02, C03BA03, C03BA04, C03BA05, C03BA07,
C03BA08, C03BA09, C03BA10, C03BA11, C03DB01,
C03DB02, C03EA, C09BA02, C09BA03, C09BA04,
C09BA05, C09BA06, C09BA07, C09BA08, C09BA09,
C09BB, C09DB, C09DA02, C09DA03, C09DA04,
C09DA06, C09DA07,
C09DA01, C02AB01, C02AB02, C02AC01, C02AC02,
C02AC04, C02AC05, C02DB02, C02DB03, C02DB04,
C02DC01, C02DD01, C02DG01, C02KA01, C02KB01,
C02KC01, C02KD01, C02KX01, C09XA]
Hypothyroidism [H03AA01, H03AA02].
Heart disease [C07AA01, C07AA02, C07AA03,
C07AA05, C07AA06,
C07AA07, C07AA12, C07AA14, C07AA15, C07AA16,
C07AA17, C07AA19,
C07AA23, C07AA27, C07AA57, C07AB, C07AG01,
C07AG02, C07BA02, C07BA05, C07BA06, C07BA07,
C07BA12, C07BA68, C07BB02, C07BB03, C07BB04,
C07BB06, C07BB07, C07BB52, C07BG01, C07CA02,
C07CA03, C07CA17, C07CA23, C07CB02, C07CB03,
C07CB53, C07CG01, C07DA06, C07DB01, C07FA05,
C07FB02, C07FB03, C07FB07, C08CA01, C08CA02,
C08CA03, C08CA04, C08CA05, C08CA06, C08CA07,
C08CA08, C08CA09, C08CA10, C08CA11, C08CA12,
C08CA13, C08CA14, C08CA15, C08CA55,
C08CX01, C08DA01, C08DA02, C08DA51, C08DB01]
Inflammatory bowel disease [A07EC01, A07EC02,
A07EC03, A07EC04]
Liver failure [A06AD11]
Malignancies [L01AA01, L01AA02, L01AA03,
L01AA05, L01AA06,
L01AA07, L01AA08, L01AB, L01AC, L01AD, L01AG01,
L01AX
L01BA01, L01BA03, L01BA04, L01BB02, L01BB03,
L01BB04, L01BB05, L01BB06, L01BB07, L01BC, L01CA,
L01CB, L01CC01, L01CD L01CX01 L01DA01
L01DB, L01DC, L01XA, L01XB01, L01XC, L01XD01,
L01XD03, L01XD04 L01XD05 L01XD06 L01XE, L01XX,
L02BA01, L02BA02, L02BG02, L02BG03, L02BG04,
L02BG06, L02BB01, L02BB03, L02AE02, L02AE04,
L02AB01]
Migraine [N02CA01, N02CA02, N02CA04, N02CA07,
N02CA51
N02CA52, N02CA72 N02CB01, N02CC01, N02CC02,
N02CC03, N02CC04, N02CC05, N02CC06, N02CC07,
N02CX01Osteoporosis [M05BA, M05BB, M05BX03, G03XC01,
A12AX92]
Pain - Opiates [N02AA, N02AB, N02AC01, N02AC03,
N02AC04, N02AC05, N02AC52, N02AC54, N02AC74,
N02AD01, N02AD02, N02AE01, N02AF01,
N02AF02, N02AG, N02AX01, N02AX02, N02AX52,
NO2AX05]
Pain - Anti-inflammatory agents [M01AB, M01AC01,
M01AC02, M01AC04, M01AC05, M01AC06, M01AE,
M01AG, M01AH, N02BE51, NO2BA01, N02BG06]
Pancreatic insufficiency [A09AA02]
Parkinson’s disease [N04AA01, N04AA02, N04AA03,
N04AA04, N04AA05,
N04AA08, N04AA09, N04AA10, N04AA11, N04AA12,
N04AB01, N04AB02, N04AC01, N04AC30, N04BA01,
N04BA02, N04BA03, N04BA04, N04BA05, N04BA06,
N04BB01, N04BC01, N04BC02, N04BC03, N04BC04,
N04BC05, N04BC06, N04BC07, N04BD01, N04BX01,
N04BX02, N0BC09, N04BD02]
Psoriasis [D05BB01, D05BB02, D05AX]
Psychotic illness [N05AA, N05AB, N05AC, N05AD,
N05AE, N05AF, N05AG
N05AH, N05AL, N05AN01, N05AX]
Chronic airways disease [R03AC, R03AK, R03BA,
R03AB,
R03BC01, R03BC03, R03BX01, R03CA02, R03CB,
R03CC, R03CC53, R03DA, R03DB, R03DC, R03BB]
Smoking cessation [N07BA01, N07BA03]
Steroid responsive disease - Systemic corticosteroid
use [H02AB, H02AA]
Transplant [L04AA01, L04AA02, L04AA03, L04AA04,
L04AA05,
L04AA06, L04AA08, L04AA09, L04AA10, L04AA11,
L04AA12,
L04AA14, L04AA15, L04AA16, L04AA17, L04AA18,
L04AA19,
L04AA21, L04AD02, L04AX01]
Tuberculosis [J04AB04, J04AB05, J04AB30, J04AC01,
J04AC51, J04AD01, J04AD02, J04AD03, J04AK01,
J04AK02]




(T2DM): Type 2 diabetes; (OAH): Oral anti-hyperglycaemic; (HSE-PCRS): Health
Service Executive – Primary Care Reimbursement Services; (ATC): Anatomical
Therapeutic Chemical; (GMS): General Medical Scheme; (OTC): Over-the-
counter; (LTI): Long Term Illness Scheme; (DPS): Drugs Payment Scheme.
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